Randomised Trials in drug-eluting stents

Randomised Trials in drug-eluting stents

On this page you will find a list of randomised trials in drug-eluting stents published in some of the world's top cardiology and interventional cardiology journals.

1.1 - DRUG-ELUTING STENTS VS BARE METAL STENTS

  • Everolimus-eluting stents vs BMS in octogenerians: XIMA trial
  • Drug-eluting or bare-metal stents in all-comer patients with coronary artery disease: NORSTENT

1.2 - COMPARISONS DRUG-ELUTING STENTS

  • Everolimus vs paclitaxel-eluting stents: COMPARE: 5 years
  • Zotarolimus vs paclitaxel stents: ENDEAVOR IV - 5 years
  • RESOLUTE all-comers trial (ZES vs EES): RESOLUTE 4 years
  • Zotarolimus vs everolimus-eluting coronary stents: Resolute all-comers: 5 years
  • Sirolimus vs. paclitaxel-eluting stents: SORT OUT II: 10 year
  • ZES vs SES: SORT OUT III 3 years
  • ZES vs SES - 1- vs 5-year outcomes: SORT OUT III
  • Biolimus vs sirolimus stents - 5-year results: LEADERS
  • EES vs SES: SORT OUT IV
  • SORT OUT IV trial: 2 years
  • EES vs SES: SORT OUT IV trial - 3 years
  • Everolimus vs Sirolimus-eluting stents: SORT-OUT IV
  • EVOLVE trial
  • Sirolimus- versus biolimus-eluting stents: SORT-OUT VII trial
  • ZES vs EES: TWENTE trial
  • ZES vs EES – 2-year outcome: TWENTE trial
  • Resolute (ZES) vs Xience (EES): TWENTE trial - 3 years
  • EES vs SES: RESET 1 year
  • SES vs EES coronary stents: RESET 3 years
  • Biodegradable polymer SES vs durable polymer EES: TARGET I trial
  • BES vs EES: COMPARE II
  • Biodegradable polymer BES vs durable EES: COMPARE II – 3 years
  • NEVO-SES compared to PES: 2-year outcome
  • Biolimus-eluting stent vs everolimus-eluting stent: NEXT
  • Biodegradable Polymer DES vs Durable Polymer DES: NEXT 3 years
  • Biolimus-eluting stent – biodegradable vs durable coating: SORT OUT V
  • Everolimus vs paclitaxel stents – 3-year outcome: SPIRIT
  • Xience V EES – 5-year results: SPIRIT II
  • Xience V EES vs TAXUS PES – 5-year outcome: SPIRIT III
  • Biolimus A9-eluting vs everolimus-eluting stents for long lesions: LONG-DES V trial
  • Bioresorbable polymer SES vs permanent polymer EES: CENTURY II
  • PtCr-EES vs CoCr-ZES: HOST-ASSURE
  • DUTCH PEERS
  • Biodegradable polymer cobalt-chromium SES vs durable polymer cobalt-chromium SES: I-LOVE-IT 2
  • Ultrathin strut SES vs EES for stable and ACS patients: BIOSCIENCE
  • DES vs BMS for NSTE-ACS: BASKET-PROVE 2 years
  • Bioresorbable polymer-coated everolimus-eluting stent: EVOLVE II
  • Zotarolimus – vs everolimus eluting stents for all-comers. TWENTE II: 2 years
  • ZES vs BMS in uncertain DES candidates: ZEUS
  • Comparison of BVS with EES and BES: EVERBIO II
  • Titanium-nitride-oxide coated stents vs ZES: TIDE - 5 years
  • Biolimus vs EES vs BMS: BASKET-PROVE II - 2 years
  • Nobori drug eluting stent vs Taxus stent: NOBORI 1 trial 5 years
  • Polymer-free drug coated coronary stents for patients at high risk of bleeding: LEADERS FREE
  • Zotarolimus vs biolimus stents: SORT-OUT VI
  • Zotarolimus vs. Biolimus stents: SORT-OUT VI: 3 years
  • Bioresorbable EE scaffold vs EE stent: ABSORB II
  • Everolimus-eluting bioresorbable scaffolds vs everolimus-eluting metallic stents: primary results of ABSORB II 3 years
  • Everolimus-eluting bioresorbable scaffolds: ABSORB III
  • Vascular scaffolds vs Metallic stents: ABSORB China trial (Added in December 2017)
  • Bioresorbable scaffold vs metallic stent in STEMI: TROFI II trial (Added in December 2017)
  • Bioresorbable vascular scaffold vs metallic stent: ABSORB CHINA 3 years (Added in December 2017)
  • Bioresorbable scaffolds vs metallic stents: AIDA trial (Added in December 2017)
  • Vascular scaffolds vs Drug eluting stents EVERBIO II trial (Added in December 2017)
  • Biodegradable Polymer BES vs Durable EES: COMPARE II 5 years(Added in December 2017)
  • Everolimus-eluting Absorb bioresorbable scaffold vs EES. Absorb - Japan
  • ISAR-TEST 4: 5-year outcome
  • Sirolimus- and probucol-eluting versus zotarolimus-eluting stents: ISAR-TEST-5 Trial 5 years
  • Biodegradable polymer everolimus-eluting and eirolimus-eluting stents vs durable polymer zotarolimus-eluting stents: BIO-RESORT
  • Excel versus BuMA stents: PANDA III trial
  • ZES vs EES for left main disease: ISAR-LEFT MAIN-2
  • Paclitaxel vs Everolimus-eluting stents in Diabetes: TUXEDO

1.3 - DES FOR CTO

  • BMS vs SES for total coronary occlusion: PRISON II study 5 years
  • Stenting of totally occluded arteries: PRISON III - 3 years
  • SES vs EES for CTO: CIBELES
  • Randomised Comparison of Ridaforolimus-and Zotarolimus-Eluting Coronary Stents in Patients with Coronary Artery Disease (Bionics) (Added in December 2017)
  • Drug-eluting stents in elderly patients with coronary artery diease: SENIOR (Added in December 2017)

1.4 - WITH OR WITHOUT ON-SITE CARDIAC SURGERY

  • PCI at hospitals with or without on-site cardiac surgery: C-PORT
  • Non-emergency PCI at hospitals without on-site cardiac surgery: MASS-COMM

1.5 - IVUS IS ANGIOGRAPHY-GUIDED DES

  • IVUS vs angiography-guided DES: RESET
  • IVUS vs angio-guided CTO treatment: CTO-IVUS study
  • Ultrasound-guided vs Angiography-guided DES for long lesions: IVUS-XPL

1.6 - VASCULAR CLOSURE DEVICE

  • Femoral artery access complications: ISAR-CLOSURE

1.7 - ROUTINE CORONARY ANGIOGRAPHY AFTER PCI

  • Routine coronary angiography after PCI: ReACT Trial

Access these randomised trials here

Sponsored by

Biotronik